secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K/A
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001193125-24-149141
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics appoints director Lori Kunkel to Nominating Committee
--------------------------------------------------------------------------

- Dr. Lori Kunkel appointed to Nominating and Corporate Governance Committee effective May 29, 2024.
- Her board appointment was reported April 9, 2024; committee role now determined.
- Appointment follows recommendation of the Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524149141/0001193125-24-149141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524149141/d816859d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-149141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer